Loading clinical trials...
Loading clinical trials...
The goal of the current trial is to determine safety of Once-daily aripiprazole in reducing Total Tic Severity in children and adolescents with Tourette's Disorder.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
NCT07039084 · Genetic Disease, Nonverbal Communication, and more
NCT06743711 · Severe Mental Illness, Schizophrenia Spectrum &Amp; Other Psychotic Disorders, and more
NCT05176808 · Autism Spectrum Disorder, Autistic Disorder, and more
NCT07455929 · Psychotic Disorders, Schizophrenia Spectrum Disorders
NCT07460453 · Paranoia, Psychotic Disorders
Dothan, Alabama
Goodyear, Arizona
Orange, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions